Table 4.
Author, year | N | C4d | DSA | Onset (PTD) | Treatment | Patient outcome |
---|---|---|---|---|---|---|
Kamar, 2009 (3) | 2 | + | + | 6 | PP, rituximab | 1 survived, 1 died |
Wilson, 2006 (13) | 1 | + | + | 1460 | PP, Thymoglobulin, rituximab | Survived |
Watson, 2006 (4) | 1 | + | + | 1 | PP, rituximab, steroids | Died |
Rostron, 2005 (11) | 1 | +/− | + | 6 | PP, steroids, IVIG, mycophenolate | Survived |
Kozlowski, 2011 (5) | 3 | + | + | 1 | PP, rituximab, steroids, IVIG, Thymoglobulin, OKT-3 | 2 died, 1 retransplant |
N = number of patients; DSA = donor-specific antibodies; PTD = posttransplant day; PP = plasmapheresis; IVIG = intravenous immunoglobulins.